Research company Hamlet Biopharma announces that the first manufacturing batch of the drug candidate Alpha1H in Phase III quality has been approved for use in the company’s clinical trials against bladder cancer in Europe and the United States. Production has meanwhile been scaled up through collaborations with Porton Pharmaceutical Chemicals and Rechon Life Science to meet the need ahead of Phase III and future demand.The company states that the timeline has been adjusted to the study start.